Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2022-04-29
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Requirement for Leucine in Adults Over 60 Years
NCT03506126
Protein Requirements in Resistance Trained Females
NCT03397043
Determination of the UL of Leucine in Healthy Elderly Men
NCT02095080
Metabolic Availability of Lysine From White Maize
NCT02018575
Lysine Requirement of Elderly Men and Women Over 60 Years of Age
NCT02008955
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects will be weighed at the pre-study assessment and at the start of each IAAO study day to ensure accurate prescription of diets and isotopes, and to confirm weight maintenance throughout the study.
Each study will consist of a 2-day adaptation period to a prescribed diet in accordance with the energy requirement of the subject and 1-study day. The diet will provide an adequate amount of protein, of 1 g protein∙kg-1∙d-1. The 2-day adaptation period is to allow the body to adapt to an adequate amount of protein as it has been shown that protein kinetics is altered without it. Following the 2 days of adaptation is the study day where leucine intake will be randomly assigned and phenylalanine (Phe) kinetics will be measured with the use of L-\[1-13C\]phenylalanine. On this day, VCO2 will be measured by calorimetry immediately after the 5th meal for a period of 20 minutes, and a 15ml blood sample will be collected at the end of each study visit to measure plasma amino acid levels, insulin, and glucose in males and females and progesterone, and estrogen in females.
For female participants, each level of intake will be studied both in the luteal and follicular phase of their menstrual cycle (up to 14 studies in total). For the follicular phase, the study will be conducted 3-7 days immediately after the 1st day of menstrual bleeding. For the luteal phase, the study will be conducted 4-7 days before the onset of next menstrual bleeding. The IAAO study day of the luteal phase will be set on the basis of each subject's length of their menstrual cycle, and the length and regularity of their cycle will be determined during the pre-study assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Leucine intake
For this study, each participant will be randomly assigned to receive up to 7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
Leucine
7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Leucine
7 intake levels of leucine, ranging from 10 to 75 mg/kg/d.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy adult females, 18 to 39 years of age with regular menstrual cycles within in the last 12 months.
3. Willingness to participate in the study and completed the screening procedures (height, weight, fasting blood sample and medical history questionnaire).
4. No recent history of weight loss
5. BMI between 18.5 - 27 kg/m 2
6. Absence of chronic disease or acute illness that could affect protein and AA metabolism (diabetes, cancer, liver or kidney disease, HIV, acute cold or flu, COVID-19, hypo or hyperthyroidism, rheumatoid arthritis treated with anti-inflammatory medications).
7. Non-smoking
8. Willingness to consume the diet provided.
Exclusion Criteria
2. On medications known to affect protein and amino acid metabolism (steroids) or taking oral contraceptive pills or other birth control devices that would affect sex hormone profiles over the last 2 years.
3. Pregnant or lactating women.
4. Recent significant weight loss; ≥ 5% of body with in the last 3 months.
5. Individuals on weight reducing diets.
6. Inability to tolerate the diet
7. Unwilling to have blood drawn from a venous access, or using a ventilated hood indirect calorimeter for the purposes of the study.
8. Significant coffee consumption of more than 2 cups/day
9. Significant alcohol consumption of more than one drink/day
10. Failure to disclose any of the information needed to assess eligibility.
18 Years
39 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
The Hospital for Sick Children
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Glenda Courtney-Martin
Associate Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Glenda Courtney-Martin, PhD, RD
Role: PRINCIPAL_INVESTIGATOR
The Hospital for Sick Children
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Hospital for Sick Children
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Szwiega S, Pencharz PB, Xu L, Kong D, Tomlinson C, Elango R, Courtney-Martin G. Leucine requirement determined in healthy young adult males using the indicator amino acid oxidation method. Am J Clin Nutr. 2024 Nov;120(5):1063-1070. doi: 10.1016/j.ajcnut.2024.08.022. Epub 2024 Aug 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1000078896
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.